Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Volition’s first supply and licensing contract for Nu.Q screening test in Asia

Volition’s first supply and licensing contract for Nu.Q screening test in Asia

Volition is a multinational epigenetics company that applies its Nucleosomics platform through subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis, such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on diagnostics and monitoring in humans but also has a subsidiary focused on animals.

In this video, we talk to Dr Tom Butera, chief executive officer of Volition Veterinary, about the company’s first supply and licensing contract for its Nu.Q vet cancer screening test. The contract is with SAGE Healthcare, a leading distributor of premium veterinary products and services in Asia.

< Previous
Next >

You may also be interested in these:

Healthcare

Recce Pharmaceuticals – executive interview

TMT

VEON – executive interview with CFO Joop Brakenhoff

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free